|
TAS::75 0849::TAS ADMINISTRATIVE MODIFICATION
|
261200800001E
|
$313,286,406
|
$37,616
|
DMITROVSKY, ETHAN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
|
5UM1CA154967-08
|
$4,864,165
|
|
CHEEVER, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Childrens Oncology Group Pediatric Early Phase Clinical Trial Network
|
1UM1CA228823-01
|
$4,739,780
|
|
WEIGEL, BRENDA
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
AIDS and Cancer Specimen Resource (ACSR)
|
3UM1CA181255-05S1
|
$3,000,000
|
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer
|
5P50CA097274-17
|
$2,500,000
|
|
WEINER, GEORGE
|
UNIVERSITY OF IOWA
|
|
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
|
5P50CA211024-02
|
$2,283,108
|
|
RUBIN, MARK
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
SPORE in Cervical Cancer
|
5P50CA098252-15
|
$2,251,770
|
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA217685-02
|
$1,813,624
|
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Shanghai Womens Health Study
|
5UM1CA182910-06
|
$1,268,648
|
|
ZHENG, WEI
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Diesel Exhaust in Miners Study II
|
ZIA CP010120 10762
|
$1,229,164
|
|
Silverman, Debra
|
DCEG (NCI)
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-09
|
$1,192,031
|
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
|
4R44CA221554-02
|
$1,161,570
|
|
WATERHOUSE, RIKKI
|
MODULATION THERAPEUTICS, INC.
|
|
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry
|
5U01CA196390-04
|
$1,122,515
|
|
PIENTA, KENNETH
|
JOHNS HOPKINS UNIVERSITY
|
|
Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the Pancreas
|
5U01CA196403-04
|
$1,107,123
|
|
MAITRA, ANIRBAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
|
5R35CA220500-02
|
$1,032,000
|
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
|
5U01CA214254-02
|
$1,020,224
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
|
5U01CA217885-02
|
$1,014,721
|
|
TAMAYO, PABLO
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Head and neck cancer
|
ZIA CP010213 10463
|
$1,001,660
|
|
Chaturvedi, Anil
|
DCEG (NCI)
|
|
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease
|
4R44CA210882-02
|
$1,000,000
|
|
LEE, JAMES
|
ID4PHARMA, LLC
|
|
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)
|
3U01DK108328-04S2
|
$1,000,000
|
|
YUAN, YING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A novel protein engineering tool for rapid manufacturing of designer nucleosomes
|
2R44CA214076-02
|
$999,997
|
|
KEOGH, MICHAEL-CHRISTOPHER
|
EPICYPHER, INC.
|
|
Novel IL-15 Superagonist Therapy for Bladder Cancer
|
6R44CA156740-05
|
$999,919
|
|
RHODE, PETER
|
ALTOR BIOSCIENCE. LLC
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
A Novel PET Probe for Use in Cancer Diagnostics
|
5R44CA216539-03
|
$999,412
|
|
MOORE, MELISSA
|
SOFIE BIOSCIENCES, INC.
|
|
Detecting breast cancer with a simple blood test using an accessible and low-cost novel real-time platform
|
4R44CA217447-02
|
$996,518
|
|
THIRUPPATHI, EAGAPPANATH
|
INANOVATE, INC.
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
|
5R44CA203068-03
|
$993,966
|
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
Point-of-Care Diagnostic Tools to Improve Global Cervical Cancer Control Programs
|
5UH3CA189910-05
|
$991,122
|
|
SCHMELER, KATHLEEN
|
RICE UNIVERSITY
|
|
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
|
5U01CA217846-02
|
$974,850
|
|
BADER, JOEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel targeted Chemotherapeutics for Gliobastoma
|
5R44CA174129-03
|
$968,230
|
|
KOLLER, KERRY
|
QUADRIGA BIOSCIENCES, INC.
|
|
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development
|
2R44CA203090-02
|
$963,578
|
|
UNGER, EVAN
|
NUVOX PHARMA, LLC
|
|
HARNESSING HOST RESPONSE TO PREVENT MYELOMA
|
7R35CA197603-03
|
$936,000
|
|
DHODAPKAR, MADHAV
|
EMORY UNIVERSITY
|
|
Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma
|
5U01CA220378-02
|
$929,069
|
|
SWANSON, KRISTIN
|
MAYO CLINIC ARIZONA
|
|
Targeting DNA damage response pathways for the treatment of advanced lung cancer
|
9R44CA228756-02
|
$924,071
|
|
KEENEY, DIANE
|
CUMBERLAND PHARMACEUTICALS, INC.
|
|
A single-cell device to capture and analyze rare T-cells from solid tumors.
|
5R44CA199055-03
|
$920,072
|
|
MCCONNELL, TIMOTHY
|
ISOPLEXIS, INC.
|
|
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
|
5R35CA210084-02
|
$915,000
|
|
DIPERSIO, JOHN
|
WASHINGTON UNIVERSITY
|
|
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium
|
5U54CA190165-05
|
$864,483
|
|
KIRK, GREGORY
|
JOHNS HOPKINS UNIVERSITY
|
|
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments
|
5U01CA215848-02
|
$825,581
|
|
KEMP, MELISSA
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
|
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing
|
4R44CA221426-02
|
$823,853
|
|
WILLIAMS, LINDSEY
|
TWINSTRAND BIOSCIENCES, INC.
|
|
Agricultural Health Study - Biomarkers of Exposures and Effects in Agriculture
|
ZIA CP010119 10527
|
$813,241
|
$813,241
|
Hofmann, Jonathan
|
DCEG (NCI)
|
|
Early Life Exposures in Agriculture
|
ZIA CP010119 10737
|
$793,079
|
$634,463
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
IND-Enabling Studies of ZB716, an Orally Bioavailable SERD
|
2R44CA213462-02
|
$748,371
|
|
WANG, GUANGDI
|
ZENOPHARM, LLC
|
|
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer
|
5U01CA217842-02
|
$739,552
|
|
MILLS, GORDON
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
MDCT Quantification of hepatic tumor viability for assessment of cancer therapy
|
2R42CA189637-02A1
|
$726,042
|
|
WU, YIN
|
IQ MEDICAL IMAGING, LLC
|
|
Development of Reagents for Sequencing Proteins and Protein Fragments on a Next-Generation DNA Sequencer
|
2R44CA203629-02
|
$718,340
|
|
GUNDERSON, KEVIN
|
ENCODIA, INC.
|
|
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.
|
5R01CA220004-02
|
$698,964
|
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Optical Dosimeter-guided Photodynamic Therapy
|
2R44CA213607-02
|
$674,353
|
|
ZHAO, YOUBO
|
PHYSICAL SCIENCES, INC
|
|
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
|
5U54CA221204-02
|
$673,579
|
|
WOOD, CHARLES
|
UNIVERSITY OF NEBRASKA LINCOLN
|
Total relevant funding to Pesticides for this search: $2,503,328
|